What Myriad means for gene patenting

June 30, 2010

The decision by a New York court in Myriad earlier this year left applicants facing an uphill battle to patent gene sequences. Michael Gollin and Rae Fischer explain how IP owners in the biotech sector can maximise protection for their innovations

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login

A New York federal court heard oral arguments this week in a copyright case pitting publishing giants against a digital library

Rory O’Neill, March 22, 2023

Commissioner Hamano Koichi shares his vision for the JPO and explains that IP offices must promote innovation that drives social change

Sukanya Sarkar, March 22, 2023

The Asia-Pacific awards research cycle has now begun – don’t miss on this opportunity be recognised in 2023

John Harrison, March 21, 2023

The Supreme Court, which is hearing two IP cases this week, should limit the power of US courts to rule on foreign sales

Rani Mehta, March 20, 2023

Safety standards wouldn’t lose copyright protection when named in law, so long as they were accessible for free online

Rani Mehta, March 17, 2023

In-house tech sources say Amgen v Sanofi has the potential to stifle their prosecution and litigation strategies if SCOTUS’s decision is too broad

Rani Mehta, March 17, 2023

We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP

Max Walters, March 17, 2023

The Federal Circuit said tech firms can challenge the way the USPTO implemented Fintiv, but that won’t mean much for practitioners, say counsel

Rani Mehta, March 16, 2023

The England and Wales High Court handed down one of the most hotly anticipated FRAND rulings for some time

Max Walters, March 16, 2023

Funders discuss different IP portfolio funding options and how they decide whether to offer preferential terms and pricing

Sukanya Sarkar, March 16, 2023